CDI: THE INNOVATION IN CANCER AND NEURAL RADIOTHERAPY. THE CYBERKNIFE
According to a recent study by CDI Centro Diagnostico Italiano experts, over 89% of patients with primary prostate cancer (PSA) who underwent Cyberknife treatment (or stereotactic radiosurgery) did not experience disease recurrence for up to seven years after the treatment. […]